Novartis Diovan Split Committee Vote Gives FDA Latitude In CHF Approval

A split committee vote on whether to approve Novartis' Diovan for treatment of congestive heart failure gives FDA's cardio-renal division considerable latitude on approvability, Director Ray Lipicky, MD, suggested at the drug's Oct. 11 review.